K Pharma

4896.TTSE GROWTHPharmaceutical

Filed as K Pharma, Inc. (2023-11–2026-08)

Key numbers · FY ended 2023-12

Revenue¥1.0bn—Operating income−¥916m—Total assets¥2.9bn+24.9% YoY EPS (basic)¥-85.59-17.3% YoY

Full financial history and reports →

Stock price4896 · View chart ↗

Open the price chart on TradingView.

Latest filings

Mon, Apr 13 · JST1 filing

16:305% STAKEK Pharma · Hideyuki Okano · 11.05% → 10.03%−1.02pp

Fri, Feb 20 · JST1 filing

16:00MATERIALK Pharma · Change of independent auditor

Fri, Apr 4 · JST1 filing

16:205% STAKEK Pharma · SBI Ventures Two Co., Ltd. + 2 joint holders · 17.08% → 15.10%−1.98pp

Thu, Apr 3 · JST1 filing

16:045% STAKEK Pharma · SBI Ventures Two Co., Ltd. + 2 joint holders · 19.14% → 17.08%−2.06pp

Wed, Apr 2 · JST1 filing

16:265% STAKEK Pharma · SBI Ventures Two Co., Ltd. + 2 joint holders · 20.68% → 19.14%−1.54pp

All filings →

Major holders (5%+) · 2

Holder	Stake	Change	Filed
SBI Ventures Two Co., Ltd.	14.88%	0.00pp	2025-04-04
Hideyuki Okano	10.03%	-1.02pp	2026-04-13

Each holder's own ratio from its most recent large-shareholding report.